What's in Green Cross Corporation's pipeline?

Green Cross Corporation has 37 drugs in our index: 4 marketed, 0 filed, 19 in Phase 3, 8 in Phase 2, 6 in Phase 1.

Which companies overlap with Green Cross Corporation's portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Pfizer, Merck Sharp & Dohme LLC, Boryung Pharmaceutical Co., Ltd, Bharat Biotech International Limited.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/green-cross-corporation.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Green Cross Corporation — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Green Cross Corporation pipeline: 4 marketed, 0 filed, 19 Phase 3, 8 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 19 Phase 3 8 Phase 2 6 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Immunoglobulin G	Immunoglobulin G	marketed	Non-Standardized Plant Allergenic Extract [EPC]
Step 1	Step 1	marketed	insulin	insulin receptor	Diabetes
Step 2	Step 2	marketed	Opioid antagonist	Mu opioid receptor	Psychiatry
Shinbaro Capsule	Shinbaro Capsule	marketed
GC3110A	GC3110A	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
GCFLU Quadrivalent Inj. vaccine	GCFLU Quadrivalent Inj. vaccine	phase 3	Inactivated influenza vaccine		Immunology / Infectious Disease
GC3110A(Trivalent)	GC3110A(Trivalent)	phase 3	Therapeutic vaccine
GC1107	GC1107	phase 3	PD-L1 inhibitor	PD-L1	Oncology
Human immunoglobulin intravenous	Human immunoglobulin intravenous	phase 3	Immunoglobulin replacement therapy / Passive immunotherapy	Multiple (polyclonal IgG targeting various pathogens and immune targets)	Immunology / Infectious Disease / Hematology
GCFLU Pre-filled Syringe inj.	GCFLU Pre-filled Syringe inj.	phase 3	Inactivated influenza vaccine		Immunology / Infectious Disease
GC FLU inj.	GC FLU inj.	phase 3	Inactivated influenza vaccine		Immunology / Infectious Disease
GC Flu(Trivalent)	GC Flu(Trivalent)	phase 3	Inactivated influenza vaccine		Immunology / Infectious Disease

Therapeutic area mix

Diabetes · 6
Immunology / Infectious Disease · 5
Oncology · 3
Other · 2
Immunology / Infectious Disease / Hematology · 1
Immunology · 1
Oncology / Immunology · 1
Psychiatry · 1
Virology / Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 7 shared drug classes
Pfizer · 5 shared drug classes
Merck Sharp & Dohme LLC · 4 shared drug classes
Boryung Pharmaceutical Co., Ltd · 3 shared drug classes
Bharat Biotech International Limited · 3 shared drug classes
Chiang Mai University · 3 shared drug classes
Novartis · 3 shared drug classes
SK Chemicals Co., Ltd. · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Green Cross Corporation:

Cite this brief

Drug Landscape (2026). Green Cross Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/green-cross-corporation. Accessed 2026-05-16.